Active Filter(s):
Details:
CATUMAXOMAB would be the first specific immunotherapy for non muscleinvasive bladder cancer, an indication with an extremely high unmet medical need.
Lead Product(s): Catumaxomab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2021